Recomendaciones SER sobre prevención de infección en enfermedades reumáticas autoinmunes sistémicas

Falagas, 2007, Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review, Clin Rheumatol., 26, 663, 10.1007/s10067-006-0441-9 Lee, 2016, Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis, Lupus., 25, 727, 10.1177/0961203315627202 Alarcón, 2006, Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis, Infect Dis Clin North Am., 20, 849, 10.1016/j.idc.2006.09.007 Garen, 2019, Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides, Rheumatology (Oxford, England)., 58, 313, 10.1093/rheumatology/key285 Yurkovich, 2014, Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies, Arthritis Care Res (Hoboken)., 66, 608, 10.1002/acr.22173 Kang, 2003, Infectious complications in SLE after immunosuppressive therapies, Curr Opin Rheumatol., 15, 528, 10.1097/00002281-200309000-00002 Ross, 1984, Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency, Medicine., 63, 243, 10.1097/00005792-198409000-00001 Rúa-Figueroa, 2014, Clinical and immunogenetic factors associated with pneumonia in patients with systemic lupus erythematosus: a case-control study, J Rheumatol., 41, 1801, 10.3899/jrheum.131470 García-Carrasco, 2019, Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis, Autoimmun Rev., 18, 184, 10.1016/j.autrev.2018.09.001 Rúa-Figueroa, 2017, Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study, Arthritis Care Res (Hoboken)., 69, 38, 10.1002/acr.23015 Leandro, 2020, Infections Related to Biologics: Agents Targeting B Cells, Infect Dis Clin North Am., 34, 161, 10.1016/j.idc.2020.02.013 Her, 2016, Alterations in immune function with biologic therapies for autoimmune disease, J Allergy Clin Immunol., 137, 19, 10.1016/j.jaci.2015.10.023 Furer, 2019, RMD open., 5, e001041, 10.1136/rmdopen-2019-001041 Bouza, 2001, Infections in systemic lupus erythematosus and rheumatoid arthritis, Infect Dis Clin North Am., 15, 335, 10.1016/S0891-5520(05)70149-5 Sui, 2014, Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population, J Viral Hepat., 21, 925, 10.1111/jvh.12302 Zhao, 2010, Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China, Rheumatol Int., 30, 1565, 10.1007/s00296-009-1188-9 Rúa-Figueroa, 2017, Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus, Semin Arthritis Rheum., 47, 38, 10.1016/j.semarthrit.2017.01.010 Juárez, 2003, Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis, Rheum Dis Clin North Am., 29, 163, 10.1016/S0889-857X(02)00100-X Cuchacovich, 2009, Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus, Rheum Dis Clin North Am., 35, 75, 10.1016/j.rdc.2009.03.003 Hsu, 2019, Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study, Arthritis Res Ther., 21, 211, 10.1186/s13075-019-1997-5 Shigayeva, 2016, Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs, Clin Infect Dis., 62, 139, 10.1093/cid/civ803 Fiore, 2010, Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010, MMWR Recomm Rep., 59, 1 Mohammad, 2017, Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis, J Rheumatol., 44, 1468, 10.3899/jrheum.160909 Torres-Aguilar, 2019, Infections as triggers of flares in systemic autoimmune diseases: novel innate immunity mechanisms, Curr Opin Rheumatol., 31, 525, 10.1097/BOR.0000000000000630 Torres-Ruiz, 2018, Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study, Lupus., 27, 312, 10.1177/0961203317720527 Doria, 2008, Infections as triggers and complications of systemic lupus erythematosus, Autoimmun Rev., 8, 24, 10.1016/j.autrev.2008.07.019 Liao, 2016, Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis, PloS one., 11, e0147856, 10.1371/journal.pone.0147856 Rondaan, 2019, Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations, RMD open., 5, e001035, 10.1136/rmdopen-2019-001035 Furer, 2020, 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis., 79, 39, 10.1136/annrheumdis-2019-215882 Braga, 2019, Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases, Med Clin., 152, 502, 10.1016/j.medcli.2019.01.010 Tadros, 2017, Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study, Semin Arthritis Rheum., 46, 804, 10.1016/j.semarthrit.2016.09.009 Lin, 2018, Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study, Lupus., 27, 66, 10.1177/0961203317711009 2011 Mir-Viladrich, 2016, Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment, Arch Bronconeumol., 52, 36, 10.1016/j.arbres.2015.04.016 Sterling, 2020, Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020, MMWR Recomm Rep., 69, 1, 10.15585/mmwr.rr6901a1 Pascual-Ramos, 2006, Association between dental caries and pneumonia in patients with systemic lupus erythematosus, J Rheumatol., 33, 1996 Waszczuk, 2015, A «cocoon immunization strategy» among patients with inflammatory bowel disease, Eur J Gastroenterol Hepatol., 27, 249, 10.1097/MEG.0000000000000280 Naranjo, 2014, Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic, Rheumatol Int., 34, 93, 10.1007/s00296-013-2851-8 Serre, 2017, Nurse-led vaccination program dramatically improves pneumococcal vaccination coverage among patients with autoimmune inflammatory disorders, Eur J Intern Med., 43, e43, 10.1016/j.ejim.2017.05.023 Ruiz-Irastorza, 2009, Predictors of major infections in systemic lupus erythematosus, Arthritis Res Ther., 11, R109, 10.1186/ar2764 Pimentel-Quiroz, 2019, Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort, Lupus., 28, 1101, 10.1177/0961203319860579 Teh, 2018, Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality, Clin Rheumatol., 37, 2081, 10.1007/s10067-018-4102-6 Yeo, 2020, Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study, BMC Infect Dis., 20, 112, 10.1186/s12879-020-4826-1 Gómez-Reino, 2011, Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients, Reumatol Clin., 7, 284 Rubin, 2014, 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host, Clin Infect Dis., 58, 309, 10.1093/cid/cit816 Thomas, 2004, Pneumocystis pneumonia, N Engl J Med., 350, 2487, 10.1056/NEJMra032588 Morris, 2004, Current epidemiology of Pneumocystis pneumonia, Emerg Infect Dis., 10, 1713, 10.3201/eid1010.030985 Mansharamani, 2000, Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states, Chest., 118, 704, 10.1378/chest.118.3.704 Wolfe, 2017, Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?, Curr Rheumatol Rep., 19, 35, 10.1007/s11926-017-0664-6 Ogawa, 2005, Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy, Mod Rheumatol., 15, 91, 10.3109/PL00021707 Vananuvat, 2011, Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases, Semin Arthritis Rheum., 41, 497, 10.1016/j.semarthrit.2011.05.004 Chew, 2015, Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid, J Clin Rheumatol., 21, 72, 10.1097/RHU.0000000000000215 Yale, 1996, Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy, Mayo Clin Proc., 71, 5, 10.4065/71.1.5 Sepkowitz, 2002, Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome, Clinical Infectious Diseases., 34, 1098, 10.1086/339548 Cettomai, 2010, A survey of rheumatologists’ practice for prescribing pneumocystis prophylaxis, J Rheumatol., 37, 792, 10.3899/jrheum.090843 Park, 2018, Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids, Ann Rheum Dis., 77, 644, 10.1136/annrheumdis-2017-211796 Utsunomiya, 2017, Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial, Arthritis Res Ther., 19, 7, 10.1186/s13075-016-1206-8 Takenaka, 2013, A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases, Mod Rheumatol., 23, 752, 10.3109/s10165-012-0730-x Yamamoto, 2014, A Feasibility Study Assessing Tolerability of Daily versus Twice Weekly Trimethoprim-Sulfamethoxazole Regimen for Prophylaxis against Pneumocystis Pneumonia in Patients with Systemic Autoimmune Diseases on Glucocorticoid Therapy, Jpn J Clin Pharmacol Ther., 45, 89, 10.3999/jscpt.45.89 Maezawa, 2013, Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases, Mod Rheumatol., 23, 62, 10.3109/s10165-012-0625-x Schmajuk, 2019, Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs, Semin Arthritis Rheum., 48, 1087, 10.1016/j.semarthrit.2018.10.018 Stern, 2014, Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients, Cochrane Database Syst Rev., 2014, CD005590 Suryaprasad, 2008, When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases, Arthritis Rheum., 59, 1034, 10.1002/art.23822 Cooley, 2014, Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014, Intern Med J., 44, 1350, 10.1111/imj.12599 2004, Hepatitis B vaccines, Weekly Epidemiological Record. Relevé epidémiologique hebdomadaire., 79, 255 Ogawa, 2020, Hepatitis B Virus Reactivation Potentiated by Biologics, Infect Dis Clin North Am., 34, 341, 10.1016/j.idc.2020.02.009 Maillefert, 1999, Rheumatic disorders developed after hepatitis B vaccination, Rheumatology (Oxford, England)., 38, 978, 10.1093/rheumatology/38.10.978 Kuruma, 2007, Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus, Lupus., 16, 350, 10.1177/0961203307078225 Erkek, 2005, Response to vaccination against hepatitis B in patients with Behcet's disease, J Gastroenterol Hepatol., 20, 1508, 10.1111/j.1440-1746.2005.03903.x Ong, 2018, What is the hepatitis B vaccination regimen in chronic kidney disease?, Cleve Clin J Med., 85, 32, 10.3949/ccjm.85a.17017 2015 Schillie, 2018, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep., 67, 1, 10.15585/mmwr.rr6701a1 Kato, 2011, Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases, J Rheumatol., 38, 2209, 10.3899/jrheum.110289 Xuan, 2014, Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review, Clin Rheumatol., 33, 577, 10.1007/s10067-013-2450-9 Koffas, 2018, Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians, Clin Med., 18, 212, 10.7861/clinmedicine.18-3-212 Tse, 2009, Management of hepatitis B reactivation in patients with lupus nephritis, Rheumatol Int., 29, 1273, 10.1007/s00296-008-0823-1 Ghorbani, 2010, High hepatitis B virus load in a patient with severe polyarthritis nodosa, Hepat Mon., 10, 306 Zingarelli, 2008, Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases, Reumatismo., 60, 22 Lau, 2002, Hepatitis B associated fulminant polyarteritis nodosa: successful treatment with pulse cyclophosphamide, prednisolone and lamivudine following emergency surgery, Eur J Gastroenterol Hepatol., 14, 563, 10.1097/00042737-200205000-00016 Marinchev, 2010, Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection, BMJ Case Rep., 2010, 10.1136/bcr.09.2009.2273 Shibolet, 2002, Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers, Blood., 100, 391, 10.1182/blood.V100.2.391 Mazzaro, 2016, Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC, Dig Liver Dis., 48, 780, 10.1016/j.dld.2016.03.018 Abdulaziz, 2017, Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series, Eur J Rheumatol., 4, 194, 10.5152/eurjrheum.2017.17003 Jalili, 2009, Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab, Iran J Immunol., 6, 55 Pattullo, 2016, Prevention of Hepatitis B reactivation in the setting of immunosuppression, Clin Mol Hepatol., 22, 219, 10.3350/cmh.2016.0024 Gonzalez, 2016, Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy, Clin Infect Dis., 62, S306, 10.1093/cid/ciw043 Reddy, 2015, American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology., 148, 215, 10.1053/j.gastro.2014.10.039 Grulich, 2007, Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet (London, England)., 370, 59, 10.1016/S0140-6736(07)61050-2 Bosch, 1995, J Natl Cancer Inst., 87, 796, 10.1093/jnci/87.11.796 Santana, 2011, Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review, Clin Rheumatol., 30, 665, 10.1007/s10067-010-1606-0 Ladouceur, 2019, Malignancies in systemic lupus erythematosus: an update, Curr Opin Rheumatol., 31, 678, 10.1097/BOR.0000000000000648 Song, 2018, The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis, Arthritis Res Ther., 20, 270, 10.1186/s13075-018-1760-3 Liu, 2011, Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia, Rheumatology (Oxford, England)., 50, 343, 10.1093/rheumatology/keq304 Zard, 2014, Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature, Autoimmun Rev., 13, 730, 10.1016/j.autrev.2014.03.001 Kim, 2015, Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study, Ann Rheum Dis., 74, 1360, 10.1136/annrheumdis-2013-204993 Nath, 2007, High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients, Arthritis Rheum., 57, 619, 10.1002/art.22667 Lee, 2010, Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus, J Korean Med Sci., 25, 1431, 10.3346/jkms.2010.25.10.1431 Cirpan, 2007, Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome, Eur J Gynaecol Oncol., 28, 302 Raposo, 2016, Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review, Acta Reumatol Port., 41, 184 Mok, 2013, Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study, Ann Rheum Dis., 72, 659, 10.1136/annrheumdis-2012-201393 Mok, 2018, Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus, Vaccine., 36, 3301, 10.1016/j.vaccine.2018.04.056 Dhar, 2017, The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus, Vaccine., 35, 2642, 10.1016/j.vaccine.2017.04.001 Dhar, 2018, The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus, Human Vaccin Immunother., 14, 2318, 10.1080/21645515.2018.1469592 Soldevilla, 2012, Systemic lupus erythematosus following HPV immunization or infection?, Lupus., 21, 158, 10.1177/0961203311429556 Anaya, 2015, Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine, Clin Exp Rheumatol., 33, 545 Moreno-Pérez, 2019, [Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations], An Pediatr (Barc)., 90, 56 Grupo de trabajo vacunación en población adulta y grupos de riesgo de la Ponencia de Programa y Registro de Vacunaciones. Vacunación en grupos de riesgo de todas las edades y en determinadas situaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, julio 2018. Stankiewicz Karita, 2019, Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol, JAMA network open., 2, e190819, 10.1001/jamanetworkopen.2019.0819 Mahumud, 2019, The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia, PloS One., 14, e0223658, 10.1371/journal.pone.0223658 Shea, 2014, Rates of pneumococcal disease in adults with chronic medical conditions, Open Forum Infect Dis., 1, ofu024, 10.1093/ofid/ofu024 Wotton, 2012, Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses, J Epidemiol Community Health., 66, 1177, 10.1136/jech-2011-200168 Pugès, 2016, Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis, Rheumatology (Oxford, England)., 55, 1664, 10.1093/rheumatology/kew211 Adawi, 2019, Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis, Autoimmun Rev., 18, 73, 10.1016/j.autrev.2018.08.002 Chatham, 2017, A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus, Lupus., 26, 1483, 10.1177/0961203317703495 Karsh, 1980, Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial, Arthritis Rheum., 23, 1294, 10.1002/art.1780231111 Nived, 2018, Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment, BMC Rheumatology., 2, 12, 10.1186/s41927-018-0019-6 Mercado, 2009, Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis, J Rheumatol., 36, 1549, 10.3899/jrheum.081227 Hesselstrand, 2018, Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis, Rheumatology (Oxford, England)., 57, 625, 10.1093/rheumatology/kex471 Groh, 2017, Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study, Joint Bone Spine., 84, 643, 10.1016/j.jbspin.2016.09.019 Nived, 2017, Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy, Vaccine., 35, 3639, 10.1016/j.vaccine.2017.05.044 David Morgan, 2016, Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population, Arthritis Care Res., 68, 853, 10.1002/acr.22757 Chanouzas, 2019, Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, J Infect Dis., 219, 234, 10.1093/infdis/jiy493 Hügle, 2012, Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine, Rheumatology (Oxford, England)., 51, 761, 10.1093/rheumatology/ker388 Saeidinejad, 2018, Behcet's disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature, Scottish Med J., 63, 119, 10.1177/0036933018801215 Elkayam, 2002, Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus, Clin Infect Dis., 34, 147, 10.1086/338043 Gabay, 2011, Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study, Arthritis Rheum., 63, 1486, 10.1002/art.30325 Saad, 2011, Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases, Ann Rheum Dis., 70, 1068, 10.1136/ard.2011.150250 Huang, 2016, Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination? A Systematic Review and Meta-Analysis, Medicine., 95, e3637, 10.1097/MD.0000000000003637 Kostianovsky, 2012, Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients, Clin Exp Rheumatol., 30, S83 Mathian, 2011, Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus, Arthritis Rheum., 63, 3502, 10.1002/art.30576 Milanovic, 2013, Influenza vaccination in autoimmune rheumatic disease patients, Tohoku J Exp Med., 229, 29, 10.1620/tjem.229.29 Launay, 2013, Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine, Vaccine., 31, 3492, 10.1016/j.vaccine.2013.05.095 Chang, 2016, Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study, Sci Rep., 6, 37817, 10.1038/srep37817 Sampaio-Barros, 2018, Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis, Rheumatology (Oxford, England)., 57, 1721, 10.1093/rheumatology/kex330 Litinsky, 2012, Vaccination against influenza in patients with systemic sclerosis, Clin Exp Rheumatol., 30, S7 Setti, 2009, Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients, Vaccine., 27, 3367, 10.1016/j.vaccine.2009.01.078 Pasoto, 2013, Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome, Vaccine., 31, 1793, 10.1016/j.vaccine.2013.01.057 Brauner, 2017, H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production, Ann Rheum Dis., 76, 1755, 10.1136/annrheumdis-2016-210509 Shinjo, 2012, Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease, Vaccine., 31, 202, 10.1016/j.vaccine.2012.10.063 Guissa, 2012, Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy, Clin Exp Rheumatol., 30, 583 Miossi, 2013, Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy, Clinics (Sao Paulo, Brazil)., 68, 129, 10.6061/clinics/2013(02)OA02 Jeffs, 2015, Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis, Nephrology (Carlton, Vic)., 20, 343, 10.1111/nep.12416 Holvast, 2009, Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination, Ann Rheum Dis., 68, 873, 10.1136/ard.2008.092924 Holvast, 2010, Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis, Ann Rheum Dis., 69, 924, 10.1136/ard.2009.112813 Adler, 2012, Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study, Rheumatology (Oxford, England)., 51, 695, 10.1093/rheumatology/ker389 Crowe, 2011, Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features, Arthritis Rheum., 63, 2396, 10.1002/art.30388 Muller, 2013, Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination, Clin Exp Rheumatol., 31, 723 Borba, 2012, Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?, Rheumatology (Oxford, England)., 51, 1061, 10.1093/rheumatology/ker427 Chatham, 2012, Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial, J Rheumatol., 39, 1632, 10.3899/jrheum.111587 Urowitz, 2011, Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus, Arthritis Care Res., 63, 1517, 10.1002/acr.20599 Vista, 2012, Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus, Lupus., 21, 168, 10.1177/0961203311429554 Stassen, 2008, Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis, Nephrol Dial Transplant., 23, 654, 10.1093/ndt/gfm640 Cordero, 2017, Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial, Clin Infect Dis., 64, 829, 10.1093/cid/ciw855 Ognibene, 1995, Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis, Am J Respir Crit Care Med., 151, 795 Li, 2006, Pneumocystis carinii pneumonia in patients with connective tissue disease, J Clin Rheumatol., 12, 114, 10.1097/01.rhu.0000221794.24431.36 Weng, 2013, Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan, J Clin Rheumatol., 19, 252, 10.1097/RHU.0b013e31829d5017 Mecoli, 2017, Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience, Clin Exp Rheumatol., 35, 671 Chung, 2000, Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy, Arthritis Rheum., 43, 1841, 10.1002/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q Kronbichler, 2018, Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis, Ann Rheum Dis., 77, 1440, 10.1136/annrheumdis-2017-212861 Fischinger, 2019, Sex differences in vaccine-induced humoral immunity, Semin Immunopathol., 41, 239, 10.1007/s00281-018-0726-5 Hillman, 2012, Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old, Clin Vaccine Immunol., 19, 261, 10.1128/CVI.05208-11 Giuliano, 2015, Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years). The MAM Study, Vaccine., 33, 5640, 10.1016/j.vaccine.2015.08.072 Soybilgic, 2013, Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years, Pediatr Rheumatol Online J., 11, 29, 10.1186/1546-0096-11-29